Roche has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq? (atezolizumab) plus chemotherapy (Abraxane? [paclitaxel protein-bound particles for injectable suspension (albumin-bound);?nab-paclitaxel]) f